journal
MENU ▼
Read by QxMD icon Read
search

Lancet Infectious Diseases

journal
https://www.readbyqxmd.com/read/29331579/corrections
#1
(no author information available yet)
No abstract text is available yet for this article.
January 10, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29329957/safety-and-tolerability-of-a-novel-polyclonal-human-anti-mers-coronavirus-antibody-produced-from-transchromosomic-cattle-a-phase-1-randomised-double-blind-single-dose-escalation-study
#2
John H Beigel, Jocelyn Voell, Parag Kumar, Kanakatte Raviprakash, Hua Wu, Jin-An Jiao, Eddie Sullivan, Thomas Luke, Richard T Davey
BACKGROUND: Middle East respiratory syndrome (MERS) is a severe respiratory illness with an overall mortality of 35%. There is no licensed or proven treatment. Passive immunotherapy approaches are being developed to prevent and treat several human medical conditions where alternative therapeutic options are absent. We report the safety of a fully human polyclonal IgG antibody (SAB-301) produced from the hyperimmune plasma of transchromosomic cattle immunised with a MERS coronavirus vaccine...
January 9, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29329956/herd-immunity-hyperimmune-globulins-for-the-21st-century
#3
Sarah Tc Elliott, David B Weiner
No abstract text is available yet for this article.
January 9, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29326014/ending-tuberculosis-calls-for-leaving-no-one-behind
#4
Masoud Dara, Rony Zachariah
No abstract text is available yet for this article.
January 8, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29326013/a-cluster-of-multidrug-resistant-mycobacterium-tuberculosis-among-patients-arriving-in-europe-from-the-horn-of-africa-a-molecular-epidemiological-study
#5
Timothy M Walker, Matthias Merker, Astrid M Knoblauch, Peter Helbling, Otto D Schoch, Marieke J van der Werf, Katharina Kranzer, Lena Fiebig, Stefan Kröger, Walter Haas, Harald Hoffmann, Alexander Indra, Adrian Egli, Daniela M Cirillo, Jérôme Robert, Thomas R Rogers, Ramona Groenheit, Anne T Mengshoel, Vanessa Mathys, Marjo Haanperä, Dick van Soolingen, Stefan Niemann, Erik C Böttger, Peter M Keller
BACKGROUND: The risk of tuberculosis outbreaks among people fleeing hardship for refuge in Europe is heightened. We describe the cross-border European response to an outbreak of multidrug-resistant tuberculosis among patients from the Horn of Africa and Sudan. METHODS: On April 29 and May 30, 2016, the Swiss and German National Mycobacterial Reference Laboratories independently triggered an outbreak investigation after four patients were diagnosed with multidrug-resistant tuberculosis...
January 8, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29307514/corrections
#6
(no author information available yet)
No abstract text is available yet for this article.
January 4, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29276051/discovery-research-and-development-of-new-antibiotics-the-who-priority-list-of-antibiotic-resistant-bacteria-and-tuberculosis
#7
Evelina Tacconelli, Elena Carrara, Alessia Savoldi, Stephan Harbarth, Marc Mendelson, Dominique L Monnet, Céline Pulcini, Gunnar Kahlmeter, Jan Kluytmans, Yehuda Carmeli, Marc Ouellette, Kevin Outterson, Jean Patel, Marco Cavaleri, Edward M Cox, Chris R Houchens, M Lindsay Grayson, Paul Hansen, Nalini Singh, Ursula Theuretzbacher, Nicola Magrini
BACKGROUND: The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and mortality worldwide. Due to its large public health and societal implications, multidrug-resistant tuberculosis has been long regarded by WHO as a global priority for investment in new drugs. In 2016, WHO was requested by member states to create a priority list of other antibiotic-resistant bacteria to support research and development of effective drugs. METHODS: We used a multicriteria decision analysis method to prioritise antibiotic-resistant bacteria; this method involved the identification of relevant criteria to assess priority against which each antibiotic-resistant bacterium was rated...
December 21, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29276050/a-crucial-list-of-pathogens
#8
Glenn Tillotson
No abstract text is available yet for this article.
December 21, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29276049/dengvaxia-age-as-surrogate-for-serostatus
#9
LETTER
Maíra Aguiar, Nico Stollenwerk
No abstract text is available yet for this article.
December 21, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29273270/is-pulsed-dosing-the-answer-to-treatment-of-clostridium-difficile-infection
#10
Dale N Gerding
No abstract text is available yet for this article.
December 19, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29273269/extended-pulsed-fidaxomicin-versus-vancomycin-for-clostridium-difficile-infection-in-patients-60-years-and-older-extend-a-randomised-controlled-open-label-phase-3b-4-trial
#11
Benoit Guery, Francesco Menichetti, Veli-Jukka Anttila, Nicholas Adomakoh, Jose Maria Aguado, Karen Bisnauthsing, Areti Georgopali, Simon D Goldenberg, Andreas Karas, Gbenga Kazeem, Chris Longshaw, Jose Alejandro Palacios-Fabrega, Oliver A Cornely, Maria J G T Vehreschild
BACKGROUND: Clostridium difficile infection causes severe complications and frequently recurs. An extended-pulsed fidaxomicin regimen might facilitate sustained clinical cure by prolonging C difficile suppression and supporting gut microbiota recovery. We aimed to compare clinical outcomes of extended-pulsed fidaxomicin with standard vancomycin. METHODS: In this randomised, controlled, open-label, superiority study, we recruited hospitalised adults aged 60 years and older with confirmed C difficile infection at 86 European hospitals...
December 19, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29254863/corrections
#12
(no author information available yet)
No abstract text is available yet for this article.
December 15, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29254862/ceftazidime-avibactam-versus-meropenem-in-nosocomial-pneumonia-including-ventilator-associated-pneumonia-reprove-a-randomised-double-blind-phase-3-non-inferiority-trial
#13
Antoni Torres, Nanshan Zhong, Jan Pachl, Jean-François Timsit, Marin Kollef, Zhangjing Chen, Jie Song, Dianna Taylor, Peter J Laud, Gregory G Stone, Joseph W Chow
BACKGROUND: Nosocomial pneumonia is commonly associated with antimicrobial-resistant Gram-negative pathogens. We aimed to assess the efficacy and safety of ceftazidime-avibactam in patients with nosocomial pneumonia, including ventilator-associated pneumonia, compared with meropenem in a multinational, phase 3, double-blind, non-inferiority trial (REPROVE). METHODS: Adults with nosocomial pneumonia (including ventilator-associated pneumonia), enrolled at 136 centres in 23 countries, were randomly assigned (1:1) to 2000 mg ceftazidime and 500 mg avibactam (by 2 h intravenous infusion every 8 h) or 1000 mg meropenem (by 30-min intravenous infusion every 8 h) for 7-14 days; regimens were adjusted for renal function...
December 15, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29254861/ceftazidime-avibactam-versus-meropenem-for-the-treatment-of-nosocomial-pneumonia
#14
Andre C Kalil, Michael Klompas
No abstract text is available yet for this article.
December 15, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29242092/zika-virus-and-microcephaly-where-do-we-go-from-here
#15
Federico Costa, Albert I Ko
No abstract text is available yet for this article.
December 11, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29242091/association-between-microcephaly-zika-virus-infection-and-other-risk-factors-in-brazil-final-report-of-a-case-control-study
#16
Thalia Velho Barreto de Araújo, Ricardo Arraes de Alencar Ximenes, Demócrito de Barros Miranda-Filho, Wayner Vieira Souza, Ulisses Ramos Montarroyos, Ana Paula Lopes de Melo, Sandra Valongueiro, Maria de Fátima Pessoa Militão de Albuquerque, Cynthia Braga, Sinval Pinto Brandão Filho, Marli Tenório Cordeiro, Enrique Vazquez, Danielle di Cavalcanti Souza Cruz, Claudio Maierovitch Pessanha Henriques, Luciana Caroline Albuquerque Bezerra, Priscila Mayrelle da Silva Castanha, Rafael Dhalia, Ernesto Torres Azevedo Marques-Júnior, Celina Maria Turchi Martelli, Laura Cunha Rodrigues
BACKGROUND: A Zika virus epidemic emerged in northeast Brazil in 2015 and was followed by a striking increase in congenital microcephaly cases, triggering a declaration of an international public health emergency. This is the final report of the first case-control study evaluating the potential causes of microcephaly: congenital Zika virus infection, vaccines, and larvicides. The published preliminary report suggested a strong association between microcephaly and congenital Zika virus infection...
December 11, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29229440/post-exposure-prophylaxis-with-doxycycline-to-prevent-sexually-transmitted-infections-in-men-who-have-sex-with-men-an-open-label-randomised-substudy-of-the-anrs-ipergay-trial
#17
Jean-Michel Molina, Isabelle Charreau, Christian Chidiac, Gilles Pialoux, Eric Cua, Constance Delaugerre, Catherine Capitant, Daniela Rojas-Castro, Julien Fonsart, Béatrice Bercot, Cécile Bébéar, Laurent Cotte, Olivier Robineau, François Raffi, Pierre Charbonneau, Alexandre Aslan, Julie Chas, Laurence Niedbalski, Bruno Spire, Luis Sagaon-Teyssier, Diane Carette, Soizic Le Mestre, Veronique Doré, Laurence Meyer
BACKGROUND: Increased rates of sexually transmitted infections (STIs) have been reported among men who have sex with men. We aimed to assess whether post-exposure prophylaxis (PEP) with doxycycline could reduce the incidence of STIs. METHODS: All participants attending their scheduled visit in the open-label extension of the ANRS IPERGAY trial in France (men aged 18 years or older having condomless sex with men and using pre-exposure prophylaxis for HIV with tenofovir disoproxil fumarate plus emtricitabine) were eligible for inclusion in this open-label randomised study...
December 8, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29229439/doxycycline-post-exposure-prophylaxis-let-the-debate-begin
#18
Christopher K Fairley, Eric P F Chow
No abstract text is available yet for this article.
December 8, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29223584/tuberculosis-eradication-renewed-commitment-and-global-investment-required
#19
Helen Cox, Mark P Nicol
No abstract text is available yet for this article.
December 6, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29223583/the-global-burden-of-tuberculosis-results-from-the-global-burden-of-disease-study-2015
#20
(no author information available yet)
BACKGROUND: An understanding of the trends in tuberculosis incidence, prevalence, and mortality is crucial to tracking of the success of tuberculosis control programmes and identification of remaining challenges. We assessed trends in the fatal and non-fatal burden of tuberculosis over the past 25 years for 195 countries and territories. METHODS: We analysed 10 691 site-years of vital registration data, 768 site-years of verbal autopsy data, and 361 site-years of mortality surveillance data using the Cause of Death Ensemble model to estimate tuberculosis mortality rates...
December 6, 2017: Lancet Infectious Diseases
journal
journal
20187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"